Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Ocular Hypertensive Subjects

NCT04140279 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.

NCT NCT04140279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04140279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Ocular Hypertensive Subjects
Lead sponsor
Bausch & Lomb Incorporated
Phase
Phase 4
Overall status
Withdrawn
Start date
May 13, 2022
Completion date
August 31, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension